Revisiting remyelination: Towards a consensus on the regeneration of CNS myelin.


Journal

Seminars in cell & developmental biology
ISSN: 1096-3634
Titre abrégé: Semin Cell Dev Biol
Pays: England
ID NLM: 9607332

Informations de publication

Date de publication:
08 2021
Historique:
received: 15 06 2020
revised: 18 09 2020
accepted: 22 09 2020
pubmed: 22 10 2020
medline: 9 2 2022
entrez: 21 10 2020
Statut: ppublish

Résumé

The biology of CNS remyelination has attracted considerable interest in recent years because of its translational potential to yield regenerative therapies for the treatment of chronic and progressive demyelinating diseases such as multiple sclerosis (MS). Critical to devising myelin regenerative therapies is a detailed understanding of how remyelination occurs. The accepted dogma, based on animal studies, has been that the myelin sheaths of remyelination are made by oligodendrocytes newly generated from adult oligodendrocyte progenitor cells in a classical regenerative process of progenitor migration, proliferation and differentiation. However, recent human and a growing number of animal studies have revealed a second mode of remyelination in which mature oligodendrocytes surviving within an area of demyelination are able to regenerate new myelin sheaths. This discovery, while opening up new opportunities for therapeutic remyelination, has also raised the question of whether there are fundamental differences in myelin regeneration between humans and some of the species in which experimental remyelination studies are conducted. Here we review how this second mode of remyelination can be integrated into a wider and revised framework for understanding remyelination in which apparent species differences can be reconciled but that also raises important questions for future research.

Identifiants

pubmed: 33082115
pii: S1084-9521(20)30157-9
doi: 10.1016/j.semcdb.2020.09.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-9

Subventions

Organisme : Medical Research Council
ID : MC_PC_12009
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17230
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P006272/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214244/Z/18/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Robin J M Franklin (RJM)

Wellcome-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom. Electronic address: rjf1000@cam.ac.uk.

Jonas Frisén (J)

Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden. Electronic address: jonas.frisen@ki.se.

David A Lyons (DA)

Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: David.Lyons@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH